JosÃ© L Arias

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4041480/publications.pdf

Version: 2024-02-01

82 papers	5,341 citations	101384 36 h-index	82410 72 g-index
83 all docs	83 docs citations	83 times ranked	8764 citing authors

#	Article	IF	Citations
1	Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines. Nanomaterials, 2022, 12, 354.	1.9	35
2	Nanomedicine for vaginal drug delivery. , 2021, , 235-257.		3
3	A Tri-Stimuli Responsive (Maghemite/PLGA)/Chitosan Nanostructure with Promising Applications in Lung Cancer. Pharmaceutics, 2021, 13, 1232.	2.0	10
4	Engineering of stealth (maghemite/PLGA)/chitosan (core/shell)/shell nanocomposites with potential applications for combined MRI and hyperthermia against cancer. Journal of Materials Chemistry B, 2021, 9, 4963-4980.	2.9	15
5	Gemcitabine-Loaded Magnetically Responsive Poly(Îµ-caprolactone) Nanoparticles against Breast Cancer. Polymers, 2020, 12, 2790.	2.0	17
6	Nanotechnology for vaginal drug delivery and targeting. , 2020, , 647-682.		7
7	First steps in the formulation of praziquantel nanosuspensions for pharmaceutical applications. Pharmaceutical Development and Technology, 2020, 25, 892-898.	1.1	4
8	An update on liposomes in drug delivery: a patent review (2014-2018). Expert Opinion on Therapeutic Patents, 2019, 29, 891-907.	2.4	74
9	Nano-engineering of biomedical prednisolone liposomes: evaluation of the cytotoxic effect on human colon carcinoma cell lines. Journal of Pharmacy and Pharmacology, 2018, 70, 488-497.	1.2	4
10	Formulation and in vitro evaluation of magnetoliposomes as a potential nanotool in colorectal cancer therapy. Colloids and Surfaces B: Biointerfaces, 2018, 171, 553-565.	2.5	30
11	Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(Îµ-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study. European Journal of Pharmaceutical Sciences, 2017, 102, 24-34.	1.9	49
12	Development and Characterization of Magnetite/Poly(butylcyanoacrylate) Nanoparticles for Magnetic Targeted Delivery of Cancer Drugs. AAPS PharmSciTech, 2017, 18, 3042-3052.	1.5	9
13	Design and characterization of a magnetite/PEI multifunctional nanohybrid as non-viral vector and cell isolation system. International Journal of Pharmaceutics, 2017, 518, 270-280.	2.6	9
14	Development of biomedical 5-fluorouracil nanoplatforms for colon cancer chemotherapy: Influence of process and formulation parameters. International Journal of Pharmaceutics, 2017, 530, 155-164.	2.6	16
15	Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. International Journal of Pharmaceutics, 2017, 516, 61-70.	2.6	110
16	Magnetic solid lipid nanoparticles in hyperthermia against colon cancer. International Journal of Pharmaceutics, 2016, 504, 11-19.	2.6	61
17	Advanced Engineering Approaches in the Development of PLGA-Based Nanomedicines. , 2016, , 1009-1039.		3
18	Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles. International Journal of Nanomedicine, 2015, 10, 1291.	3.3	40

#	Article	IF	Citations
19	Enhanced antitumoral activity of doxorubicin against lung cancer cells using biodegradable poly(butylcyanoacrylate) nanoparticles. Drug Design, Development and Therapy, 2015, 9, 6433.	2.0	28
20	Advanced Engineering Approaches in the Development of PLGA-Based Nanomedicines. , 2015, , 1-25.		2
21	In vitro and in vivo evaluation of Î”9-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy. International Journal of Pharmaceutics, 2015, 487, 205-212.	2.6	44
22	Poly(butylcyanoacrylate) and Poly(Îµ-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer. AAPS Journal, 2015, 17, 918-929.	2.2	28
23	Iron oxide-based multifunctional nanoparticulate systems for biomedical applications: a patent review (2008 â€“ present). Expert Opinion on Therapeutic Patents, 2015, 25, 691-709.	2.4	27
24	Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis. Journal of Controlled Release, 2015, 197, 190-198.	4.8	68
25	Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis. PLoS Pathogens, 2015, 11, e1004942.	2.1	63
26	Nano-Sized Platforms for Vaginal Drug Delivery. Current Pharmaceutical Design, 2015, 21, 1633-1644.	0.9	22
27	Engineering of Î” 9 -tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms. Colloids and Surfaces B: Biointerfaces, 2014, 123, 114-122.	2.5	23
28	Liposomes in drug delivery: a patent review (2007 â€“ present). Expert Opinion on Therapeutic Patents, 2013, 23, 1399-1414.	2.4	51
29	RNA Interference in the Treatment of Colon Cancer. BioDrugs, 2013, 27, 317-327.	2.2	14
30	Biocompatible gemcitabine-based nanomedicine engineered by Flow FocusingÂ® for efficient antitumor activity. International Journal of Pharmaceutics, 2013, 443, 103-109.	2.6	36
31	Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 329-338.	2.0	77
32	Multifunctional Anticancer Nanomedicine Based on a Magnetically Responsive Cyanoacrylate Polymer. Methods in Enzymology, 2012, 508, 61-88.	0.4	4
33	Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 1058-1070.	0.9	106
34	Drug Delivery to Inflammation Based on Nanoparticles Surface Decorated with Biomolecules. Current Medicinal Chemistry, 2012, 19, 3203-3211.	1.2	14
35	Drug Targeting to Cancer by Nanoparticles Surface Functionalized with Special Biomolecules. Current Medicinal Chemistry, 2012, 19, 3188-3195.	1.2	43
36	Editorial [Hot Topic: Chemical Engineering of Nanocarrier Surfaces for an Efficient Drug Delivery to Severe Diseases (Guest Editor: Jose L. Arias)]. Current Medicinal Chemistry, 2012, 19, 3069-3069.	1.2	1

#	Article	IF	Citations
37	Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications. Chemical Reviews, 2012, 112, 5818-5878.	23.0	1,769
38	5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer. International Journal of Nanomedicine, 2012, 7, 95.	3.3	34
39	Fe3O4/chitosan nanocomposite for magnetic drug targeting to cancer. Journal of Materials Chemistry, 2012, 22, 7622.	6.7	132
40	Maghemite/poly(d,l-lactide-co-glycolyde) composite nanoplatform for therapeutic applications. Journal of Nanoparticle Research, 2012, 14, 1.	0.8	19
41	Synthesis of a Biodegradable Magnetic Nanomedicine Based on the Antitumor Molecule Tegafur. Medicinal Chemistry, 2012, 8, 516-523.	0.7	4
42	Squalene Based Nanocomposites: A New Platform for the Design of Multifunctional Pharmaceutical Theragnostics. ACS Nano, 2011, 5, 1513-1521.	7.3	141
43	Advanced methodologies to formulate nanotheragnostic agents for combined drug delivery and imaging. Expert Opinion on Drug Delivery, 2011, 8, 1589-1608.	2.4	43
44	Insulin-loaded PLGA microparticles: flow focusingversusdouble emulsion/solvent evaporation. Journal of Microencapsulation, 2011, 28, 430-441.	1.2	37
45	Superior Preclinical Efficacy of Gemcitabine Developed As Chitosan Nanoparticulate System. Biomacromolecules, 2011, 12, 97-104.	2.6	53
46	Editorial [Hot Topic: Drug Delivery Strategies in Targeting Cancer:Current Concepts and Future Developments (Guest Editor: Jose L. Arias)]. Current Drug Targets, 2011, 12, 1094-1095.	1.0	7
47	Drug Targeting Strategies in Cancer Treatment: An Overview. Mini-Reviews in Medicinal Chemistry, 2011, 11, 1-17.	1.1	139
48	Lipid-Based Drug Delivery Systems for Cancer Treatment. Current Drug Targets, 2011, 12, 1151-1165.	1.0	76
49	Multifunctional antitumor magnetite/chitosan-l-glutamic acid (core/shell) nanocomposites. Journal of Nanoparticle Research, 2011, 13, 4311-4323.	0.8	21
50	Biodegradable polymeric nanoformulation based on the antiprotozoal canthin-6-one. Journal of Nanoparticle Research, 2011, 13, 6737-6746.	0.8	8
51	Engineering of an antitumor (core/shell) magnetic nanoformulation based on the chemotherapy agent ftorafur. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2011, 384, 157-163.	2.3	27
52	Possibilities of Poly(D,L-lactide-co-glycolide) in the Formulation of Nanomedicines Against Cancer. Current Drug Targets, 2011, 12, 1096-1111.	1.0	20
53	Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. International Journal of Clinical Pharmacy, 2010, 32, 559-561.	1.4	36
54	Role of the electrokinetic properties on the stability of mebendazole suspensions for veterinary applications. International Journal of Pharmaceutics, 2010, 393, 162-167.	2.6	3

#	Article	IF	Citations
55	Formulation and physicochemical characterization of poly(É›-caprolactone) nanoparticles loaded with ftorafur and diclofenac sodium. Colloids and Surfaces B: Biointerfaces, 2010, 75, 204-208.	2.5	20
56	Iron/ethylcellulose (core/shell) nanoplatform loaded with 5-fluorouracil for cancer targeting. Colloids and Surfaces B: Biointerfaces, 2010, 77, 111-116.	2.5	38
57	Skin Creams Made with Olive Oil. , 2010, , 1133-1141.		10
58	Chitosan nanoparticles as a new delivery system for the chemotherapy agent tegafur. Drug Development and Industrial Pharmacy, 2010, 36, 744-750.	0.9	35
59	Formulation of Chitosan Nanoparticles Loaded with Metronidazole for the Treatment of Infectious Diseases. Letters in Drug Design and Discovery, 2010, 7, 70-78.	0.4	9
60	Protein-loaded PLGA microparticles engineered by flow focusing: Physicochemical characterization and protein detection by reversed-phase HPLC. International Journal of Pharmaceutics, 2009, 380, 147-154.	2.6	28
61	Development of iron/ethylcellulose (core/shell) nanoparticles loaded with diclofenac sodium for arthritis treatment. International Journal of Pharmaceutics, 2009, 382, 270-276.	2.6	75
62	Study of the stability of KollidonÂ® SR suspensions for pharmaceutical applications. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2009, 338, 107-113.	2.3	15
63	KollidonÂ® SR colloidal particles as vehicles for oral morphine delivery in pain treatment. Colloids and Surfaces B: Biointerfaces, 2009, 70, 207-212.	2.5	7
64	Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. Journal of Drug Targeting, 2009, 17, 586-598.	2.1	49
65	5-Fluorouracil-loaded iron/ethylcellulose (core/shell) nanoparticles for active targeting of cancer. Journal of Drug Targeting, 2009, 00, 090902081842026-10.	2.1	1
66	Magnetic Colloids As Drug Vehicles. Journal of Pharmaceutical Sciences, 2008, 97, 2948-2983.	1.6	161
67	Study of the magnetorheological response of aqueous magnetite suspensions stabilized by acrylic acid polymers. Journal of Colloid and Interface Science, 2008, 324, 199-204.	5.0	29
68	Poly(alkylcyanoacrylate) colloidal particles as vehicles for antitumour drug delivery: A comparative study. Colloids and Surfaces B: Biointerfaces, 2008, 62, 64-70.	2.5	76
69	Synthesis of lidocaine-loaded PLGA microparticles by flow focusing. International Journal of Pharmaceutics, 2008, 358, 27-35.	2.6	73
70	Study of carbonyl iron/poly(butylcyanoacrylate) (core/shell) particles as anticancer drug delivery systems. European Journal of Pharmaceutical Sciences, 2008, 33, 252-261.	1.9	38
71	Stability of fenbendazole suspensions for veterinary use. European Journal of Pharmaceutical Sciences, 2008, 34, 257-262.	1.9	19
72	Tegafur loading and release properties of magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles. Journal of Controlled Release, 2008, 125, 50-58.	4.8	78

#	Article	IF	Citations
73	Magnetoresponsive Squalenoyl Gemcitabine Composite Nanoparticles for Cancer Active Targeting. Langmuir, 2008, 24, 7512-7519.	1.6	54
74	Magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles as 5-Fluorouracil delivery systems for active targeting. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 54-63.	2.0	82
75	Novel Strategies to Improve the Anticancer Action of 5-Fluorouracil by Using Drug Delivery Systems. Molecules, 2008, 13, 2340-2369.	1.7	184
76	Ftorafur loading and controlled release from poly(ethyl-2-cyanoacrylate) and poly(butylcyanoacrylate) nanospheres. International Journal of Pharmaceutics, 2007, 337, 282-290.	2.6	47
77	Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications. International Journal of Pharmaceutics, 2007, 339, 237-245.	2.6	55
78	Colloidal Stability of Magnetite/Poly(lactic acid) Core/Shell Nanoparticles. Langmuir, 2006, 22, 2816-2821.	1.6	84
79	Preparation and characterization of carbonyl iron/poly(butylcyanoacrylate) core/shell nanoparticles. Journal of Colloid and Interface Science, 2006, 299, 599-607.	5.0	99
80	Loading of 5-Fluorouracil to Poly(ethyl-2-cyanoacrylate) Nanoparticles with a Magnetic Core. Journal of Biomedical Nanotechnology, 2005, 1, 214-223.	0.5	26
81	Aging Effects in the Electrokinetics of Colloidal Iron Oxides. Journal of Colloid and Interface Science, 2002, 245, 86-90.	5.0	52
82	Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. Journal of Controlled Release, 2001, 77, 309-321.	4.8	180